nQ is committed to brave research
Our focus is the discovery, development, and commercialization of computationally-derived digital biomarkers for people living with neurodegenerative diseases.
nQ Medical, Inc. is pioneering digital biomarker development to accelerate research, advance disease detection, and improve care. nQ’s Digital Neurology is powered by AI analysis of passive personal device interactions. Based on research begun at MIT, our first computationally derived digital biomarker for Parkinson's disease has received FDA Breakthrough Designation and our de novo application will be submitted at the end of March 2022. FDA clearance is expected within six months; the Software As a Medical Device (SaMD) was submitted in the market March 2022.
nQ's goal is to bring accurate, affordable, and accessible digital tools to people everywhere. This supports a broad range of neurodegenerative diseases (as well as other disorders involving motor function and cognition) in early detection, remote patient monitoring, and improved treatment pathways. Our NeuroCare product helps health systems deliver digital neurology outside the four walls of the hospital.
We have assembled an exceptional team of data scientists, engineers, neurologists, and company builders who are committed to conquering one of the greatest medical challenges of our generation.
We believe in...
Improving livesCollaborationIntegrityTrustBrave ResearchAccountabilityInclusiveness
Our Vision
nQ Medical is pioneering digital biomarker development to accelerate research, enhance disease detection, and improve care.
Our Mission
To improve lives, by enabling the discovery and development of digital biomarkers.
The nQ Medical Journey
2015
NeuroQwerty
NeuroQwerty Project Launched @ MIT with Support of MJFF
2015
2016
nQ Medical, Inc
nQ Medical, Inc. founded in Kendall Square, Cambridge, MA
2017
Research Initiative Expanded
Parkinson’s Disease (PD) Research Initiative Expanded
2017
2018
US Patent Issued
US Patent 9,867,573 Issued
2018
Alzheimer’s Disease
Alzheimer’s Disease (AD) Research Initiative @ Cleveland Clinic with Support of Biogen
2018
2018
Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) Research Initiative @ MGH with Support of MT Pharma
2019
A Breakthrough
FDA Breakthrough Designation Awarded
2019
2019
Another Patent
US Patent 10,506,979 Issued
2021
Partnership
Partnership with Davis-Phinney Foundation
2021
2021
New patent Issued
US Patent 10,959,676 Issued
2022
Global
Expansion to Japan
2022
